Literature DB >> 26671506

Toxicity evaluation of high-fluorescent rare-earth metal nanoparticles for bioimaging applications.

Luis Hernandez-Adame1, Nancy Cortez-Espinosa2, Diana P Portales-Pérez2, Claudia Castillo3, Wayne Zhao4, Zaida N Juarez5, Luis R Hernandez6, Horacio Bach4, Gabriela Palestino1.   

Abstract

Research on nanometer-sized luminescent semiconductors and their biological applications in detectors and contrasting agents is an emergent field in nanotechnology. When new nanosize technologies are developed for human health applications, their interaction with biological systems should be studied in depth. Rare-earth elements are used in medical and industrial applications, but their toxic effects are not known. In this work, the biological interaction between terbium-doped gadolinium oxysulfide nanoparticles (GOSNPs) with human peripheral blood mononuclear cells (PBMC), human-derived macrophages (THP-1), and human cervical carcinoma cell (HeLa) were evaluated. The GOSNPs were synthetized using a hydrothermal method to obtain monodisperse nanoparticles with an average size of 91 ± 9 nm. Characterization techniques showed the hexagonal phase of the Gd2 O2 S:Tb3+ free of impurities, and a strong green emission at λemi  = 544 nm produced by Tb3+ was observed. Toxic effects of GOSNPs were evaluated using cell viability, apoptosis, cell-cycle progression, and immunological response techniques. In addition, an Artemia model was used to assess the toxicity in vivo. Results indicated cell apoptosis in both types of cells with less sensitivity for PBMC cells compared to HeLa cells. In addition, no toxic effects were observed in the in vivo model of Artemia. Moreover, GOSNPs significantly reduced the activation and cell-cycle progression of PBMC and HeLa cells, respectively. Interestingly, an increase in proinflammatory cytokines was not observed. Our data suggest that fluorescence applications of GOSNPs for biolabeling are not toxic in primary immune cells and they may have an immunomodulatory effect.
© 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 605-615, 2017. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  biological cells; immunomodulatory effect; oxysulfides; toxicity

Mesh:

Substances:

Year:  2015        PMID: 26671506     DOI: 10.1002/jbm.b.33577

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  5 in total

1.  Synthesis of Uniform Rare Earth Doped Gd2O2S Sub-micron Sized Spheres Using Gas-Aided Sulfurization and their Optical Characteristics.

Authors:  Shuqing He; Xinyu Zhao; Mei Chee Tan
Journal:  RSC Adv       Date:  2017-07-19       Impact factor: 3.361

2.  Rare-earth (Gd3+,Yb3+/Tm3+, Eu3+) co-doped hydroxyapatite as magnetic, up-conversion and down-conversion materials for multimodal imaging.

Authors:  Nenad L Ignjatović; Lidija Mančić; Marina Vuković; Zoran Stojanović; Marko G Nikolić; Srečo Škapin; Sonja Jovanović; Ljiljana Veselinović; Vuk Uskoković; Snežana Lazić; Smilja Marković; Miloš M Lazarević; Dragan P Uskoković
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

3.  Size-Dependent Nonlinear Optical Properties of Gd2O2S:Tb3+ Scintillators and Their Doped Gel Glasses.

Authors:  Long Chen; Cuiyu Wu; Zheng Xie; Chenghua Sun; Shuyun Zhou
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

4.  Yttrium(iii) coordination polymer micro/nanospheres with single ligand and dual ligands.

Authors:  Yanhua Ji; Qifeng Guo; Qingquan Yang; Yong Gao; Xiaojun Yan; Hongning Liu; Zhijun Zeng
Journal:  RSC Adv       Date:  2020-09-01       Impact factor: 4.036

Review 5.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.